PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 3557298
• 负责人: V M WHITEHEAD
• 金额: $ 2.56万
• 依托单位: MONTREAL CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-01-01 至 1990-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557298
• 关键词: antineoplastics; cancer registry /resource; cooperative study; cytogenetics; drug adverse effect; drug metabolism; folate; glioma; human subject; human therapy evaluation; lymphoma; lymphosarcoma; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer surgery; neuroblastoma; pediatric neoplasm /cancer; vitamin B12

Support is requested for participation in all clinical and laboratory investigative activities of the Pediatric Oncology Group (POG). Specifically, these funds will assist our efforts in cooperative cancer therapy trials which utilize a combination of surgery and/or radiation therapy and/or chemotherapy for the treatment of leukemias, lymphomas, solid tumors and brain tumors. Emphasis will be placed on integrated multi-modality treatment programs in Phase III randomized prospective studies. We shall also participate in group-wide Phase II studies of new chemotherapeutic agents. We plan to participate fully in limited Pediatric Phase I studies of new agents. (This is the subject of a contract proposal from several POG institutions, including ourselves, to the NCI). We shall participate in studies examining the biology of various pediatric malignancies including immunologic and pharmacologic features; in studies of the late effects of therapy in surviving patients; and in epidemiological studies. Support will permit us to enter the maximum number of patients on study and ensure complete documentation of patient data, including transport of specimens to reference laboratories. It will permit members to attend POG meetings and to participate in working sub-committees, protocol planning committees and study writing committees. In addition it will permit certain investigators to continue to contribute in leadership roles to the science and administration of the POG. Dr. V. Michael Whitehead is Co-Chairman of the New Agents & Pharmacology Scientific Support Committee. In this position, he directs Phase I and Phase II new agent studies. He is developing protocols to study the pharmacology of methotrexate, 6-mercaptopurine and cytosine arabinoside in children with acute lymphoblastic leukemia. He is a member of the Planning Committee for ALinC 14, the next frontline therapeutic study of acute lymphoblastic leukemia. Dr. Carol Freeman is Coordinator of the Phase I study of Hyperfractionation in Brainstem Gliomas in Children (POG 8495) and a member of the following POG committees: Institutional Performance Review Committee and the Brain Tumor Core Committee. Dr. Penny Koch is a member of the Bone Marrow Transplant Core Committee. Susan Kajaks is a member of the Data Managers Core Committee.

请求支持参与所有临床和实验室 儿科肿瘤学组 (POG) 的调查活动。 具体来说，这些资金将协助我们在癌症领域的合作努力 结合手术和/或放疗的治疗试验 用于治疗白血病、淋巴瘤的疗法和/或化疗， 实体瘤和脑肿瘤。 重点将放在综合 III期随机前瞻性多模式治疗方案 研究。 我们还将参与整个集团范围内新药的二期研究 化疗剂。 我们计划充分参与有限的儿科 新药的第一阶段研究。 （这是合同提案的主题 来自多个 POG 机构，包括我们自己，以及 NCI）。 我们将 参与检查各种儿科生物学的研究 恶性肿瘤，包括免疫学和药理学特征；在研究中 治疗对幸存患者的后期影响；并在 流行病学研究。 支持将使我们能够输入接受研究的患者的最大数量，并且 确保患者数据的完整记录，包括运输 标本送至参考实验室。 它将允许会员参加 POG 会议并参加工作小组委员会、礼宾规划 委员会和研究写作委员会。 此外，它将允许 某些调查人员继续在该项目中发挥领导作用 POG 的科学和管理。 V. Michael Whitehead 博士是新药物与药理学联合主席 科学支持委员会。 在此职位上，他负责第一阶段和 二期新药研究。 他正在开发协议来研究 甲氨蝶呤、6-巯基嘌呤和阿糖胞苷的药理学 患有急性淋巴细胞白血病的儿童。 他是规划部成员 ALiC 14 委员会，急性急性淋巴细胞白血病的下一个一线治疗研究 淋巴细胞白血病。 卡罗尔·弗里曼博士是第一阶段的协调员 儿童脑干胶质瘤超分割研究 (POG 8495) 和 以下 POG 委员会的成员： 机构绩效审查 委员会和脑肿瘤核心委员会。 彭妮·科赫博士是会员 骨髓移植核心委员会委员。 苏珊·卡亚克斯 (Susan Kajaks) 是 数据管理者核心委员会。